When 58-year-old Maria Thompson developed a severe kidney infection last winter, her doctors warned her: the usual antibiotics weren’t working like they used to. Bacteria had evolved, and her treatment options were narrowing. Now, thanks to the FDA’s recent approval of Utebzi, patients like her have a new weapon—an oral pill that could replace days in the hospital hooked to an IV. Manufactured by GSK, Utebzi (tebipenem pivoxil) is the first and only oral carbapenem antibiotic approved in the United States for complicated urinary tract infections (cUTIs), including pyelonephritis, in adults who lack effective oral alternatives.
This approval matters at a time when antibiotic resistance is rising globally, turning once-treatable infections into life-threatening conditions. The World Health Organization has flagged drug-resistant UTIs as a critical concern, and hospitals are increasingly relying on intravenous antibiotics—costly, invasive, and resource-intensive. Utebzi offers a path out of that cycle. Based on the Phase III PIVOT-PO trial, the oral medication proved noninferior to intravenous imipenem-cilastatin, a hospital-standard carbapenem. In the study, 446 patients received Utebzi and 483 received the IV treatment. The overall success rate—defined as both clinical cure and microbiological eradication—was 58.5% (261 patients) for Utebzi versus 60.2% (291 patients) for the IV therapy.
The implications are tangible: more patients could be treated at home, reducing hospital stays, lowering healthcare costs, and minimizing exposure to hospital-acquired infections. The safety profile mirrored that of other carbapenems, with diarrhea and headache as the most common side effects—both typically mild or moderate. For GSK, this marks a milestone in antibiotic innovation. "The approval of Utebzi provides the first and only oral carbapenem antibiotic for appropriate adults with complicated UTIs, a solution that could help reduce reliance on hospital-based intravenous care and support efforts to address resistant infections," said Tony Wood, chief scientific officer at GSK.
While Utebzi won’t replace all IV treatments, it opens a door for patients who’ve run out of options. It also signals a shift—toward more patient-centered, accessible care in the fight against superbugs. As resistance continues to evolve, tools like Utebzi won’t just treat infections; they’ll reshape how we deliver care.